亲爱的研友该休息了!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!身体可是革命的本钱,早点休息,好梦!

Recurrence of High-Grade Vulvar Intraepithelial Neoplasia After Treatment With Excision Compared With Imiquimod

伊米奎莫德 医学 外阴上皮内瘤变 皮肤病科 外阴 上皮内瘤变 外科 宫颈上皮内瘤变 外科切除术 癌前病变 基底细胞 并发症 口腔 妇科 化疗
作者
Hadley Reid,Stephanie Alimena,Andrea J. Pelletier,Georgia Seidman,Lawrence Hsu Lin,Shuk On Annie Leung,Carlos Parra‐Herran,Sarah Feldman
出处
期刊:Obstetrics & Gynecology [Lippincott Williams & Wilkins]
卷期号:147 (2): 151-159 被引量:6
标识
DOI:10.1097/aog.0000000000006094
摘要

OBJECTIVE: To evaluate long-term recurrence rates and time to first recurrence for human papillomavirus (HPV)-associated high-grade vulvar intraepithelial neoplasia (VIN) by initial treatment. METHODS: This was a retrospective cohort study of patients treated with excision, imiquimod, or laser for HPV-associated VIN grade 2-3 at a high-risk colposcopy center. We collected demographic, clinical, and longitudinal pathology data. Given the small number (n=15), the cohort of patients treated with laser were excluded from analyses. We performed χ 2 and Wilcoxon rank-sum tests to compare the rates of recurrence and median time to first recurrence by treatment modality. Univariate and multivariate analyses were conducted to compare predictors of recurrence and time to recurrence. Multivariate models were adjusted for side effects or barriers to imiquimod use, lesion focality, and initial histology based on significant findings in the univariate models. RESULTS: Three hundred fifteen patients met the criteria for inclusion, 231 treated with excision and 84 with imiquimod. Median follow-up time from initial diagnosis was 36 months. Recurrence rates and median time to recurrence with imiquimod (40.5% and 7.4 months) and excision (34.6% and 11.3 months, P =.34, P =.38) did not differ significantly. In univariate analysis, positive margins (odds ratio [OR] 4.68, 95% CI, 2.53-8.62), multifocal disease (OR 2.27, 95% CI, 1.19-4.33), and presence of carcinoma in situ on initial diagnosis (OR 6.21, 95% CI, 1.45-26.6) were predictors of recurrence after excision. Only the presence of side effects or barriers to imiquimod use (OR 2.46, 95% CI, 1.01-6.02) was significant in the univariate model for recurrence after imiquimod. No significant difference remained for the odds of recurrence after treatment with imiquimod compared with excision in the multivariate model (OR 1.28, 95% CI, 0.77-2.14); there was similarly no significant difference in the multivariate model of time to recurrence (hazard ratio 1.41, 95% CI, 0.86-2.30). CONCLUSION: In appropriately selected patients, imiquimod appears to have outcomes similar to those of excision for the prevention of recurrent HPV-associated VIN.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
2秒前
煊陌完成签到 ,获得积分10
5秒前
xiaoyin完成签到 ,获得积分10
6秒前
7秒前
7秒前
Lifel完成签到,获得积分10
7秒前
14秒前
16秒前
A水暖五金批发张哥完成签到,获得积分10
16秒前
Ni完成签到 ,获得积分10
17秒前
云墨完成签到 ,获得积分10
17秒前
18秒前
椰子云发布了新的文献求助10
20秒前
学术雷锋发布了新的文献求助10
23秒前
Moon完成签到 ,获得积分10
27秒前
天真的乐驹完成签到 ,获得积分10
31秒前
李健的小迷弟的应助被郦稀采纳,获得10
31秒前
Moon关注了科研通微信公众号
31秒前
32秒前
乐康完成签到,获得积分10
32秒前
35秒前
复杂惜珊完成签到,获得积分10
42秒前
cx完成签到,获得积分10
47秒前
机灵伟诚完成签到,获得积分10
47秒前
学霸业的应助被纯情的阁采纳,获得10
49秒前
极限001的应助被纯情的阁采纳,获得50
49秒前
Maestro_S的应助被纯情的阁采纳,获得10
49秒前
Nikkie2411的应助被纯情的阁采纳,获得10
49秒前
52秒前
53秒前
369ninja的应助被科研通管家采纳,获得10
55秒前
丘比特的应助被科研通管家采纳,获得10
55秒前
手打鱼丸完成签到 ,获得积分10
55秒前
55秒前
完美世界的应助被科研通管家采纳,获得10
55秒前
莫名乐乐完成签到,获得积分10
55秒前
FashionBoy的应助被科研通管家采纳,获得10
55秒前
SciGPT的应助被科研通管家采纳,获得10
55秒前
Akim的应助被纯情的阁采纳,获得10
55秒前
null的应助被科研通管家采纳,获得10
55秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1500
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
What Else Can I Tell You?: A Pragmatic Study of English Rhetorical Questions as Discursive and Argumentative Acts 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8158598
求助须知:如何正确求助?哪些是违规求助? 9554358
关于积分的说明 21719087
捐赠科研通 7748128
什么是DOI,文献DOI怎么找? 3427032
关于科研通互助平台的介绍 2551902
邀请新用户注册赠送积分活动 2471277